TP53 and neoplasm: In these prior Ad-p53 clinical trials, a total dose of 2 × 1012 viral particles per treatment was divided between the patients’ tumors at the investigators’ discretion, which lead to different tumors receiving different Ad-p53 doses by tumor volume.